Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-cateninY654 are associated with breast carcinoma: Clinical and prognostic significance

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 9, 2016, Pages 1472-1484

  Mukherjee, Nupur ^a   Dasgupta, Hemantika ^a   Bhattacharya, Rittwika ^a   Pal, Debolina ^a   Roy, Rituparna ^a   Islam, Saimul ^a   Alam, Neyaz ^a   Biswas, Jaydip ^a   Roy, Anup ^b   Roychoudhury, Susanta ^c   Panda, Chinmay Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Department of Pathology ^*  (India)

^c Saroj Gupta Cancer Centre and Research Institute   (India)

Author keywords

Breast cancer; Breast cancer subtypes; EGFR MYC CCND1; MCC CTNNBIP1; Nuclear catenin; P cateninY654

Indexed keywords

BETA CATENIN; CATENIN BETA INTERACTING PROTEIN 1; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTATED IN COLORECTAL CANCER PROTEIN; MYC PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INDIAN; MAJOR CLINICAL STUDY; MALE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

EID: 84969980411     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.05.009     Document Type: Article

References (54)

1. Mukherjee N., Bhattacharya N., Alam N., Roy A., Roychoudhury S., Panda C.K. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance. Cancer Sci. 2012, 103:210-220.
2. Sinha S., Chunder N., Mukherjee N., Alam N., Roy A., Roychoudhury S., Kumar Panda C. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. Ann. Surg. Oncol. 2008, 15:1070-1080.
3. Mukherjee N., Bhattacharya N., Sinha S., Alam N., Chakravarti R., Roychoudhury S., Panda C.K. Association of APC and MCC polymorphisms with increased breast cancer risk in an Indian population. Int. J. Biol. Markers 2011, 26:43-49.
4. Polyak K. Breast cancer: origins and evolution. J. Clin. Invest. 2007, 117:3155-3163.
5. Perou C.M., Parker J.S., Prat A., Ellis M.J., Bernard P.S. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet 2010, 11:718-719. (author reply 720-711).
6. Daniels D.L., Weis W.I. ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol. Cell 2002, 10:573-584.
7. Khramtsov A.I., Khramtsova G.F., Tretiakova M., Huo D., Olopade O.I., Goss K.H. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 2010, 176:2911-2920.
8. Geyer F.C., Lacroix-Triki M., Savage K., Arnedos M., Lambros M.B., MacKay A., Natrajan R., Reis-Filho J.S. Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol. 2011, 24:209-231.
9. Khalil S., Tan G.A., Giri D.D., Zhou X.K., Howe L.R. Activation status of Wnt/ss-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One 2012, 7.
10. Xu J., Chen Y., Huo D., Khramtsov A., Khramtsova G., Zhang C., Goss K.H., Olopade O.I. Beta-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol. Carcinog. 2015.
11. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
12. Satoh K., Kasai M., Ishidao T., Tago K., Ohwada S., Hasegawa Y., Senda T., Takada S., Nada S., Nakamura T., Akiyama T. Anteriorization of neural fate by inhibitor of beta-catenin and T cell factor (ICAT), a negative regulator of Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8017-8021.
13. Tago K., Nakamura T., Nishita M., Hyodo J., Nagai S., Murata Y., Adachi S., Ohwada S., Morishita Y., Shibuya H., Akiyama T. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev. 2000, 14:1741-1749.
14. Tutter A.V., Fryer C.J., Jones K.A. Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro. Genes Dev. 2001, 15:3342-3354.
15. Reifenberger J., Knobbe C.B., Wolter M., Blaschke B., Schulte K.W., Pietsch T., Ruzicka T., Reifenberger G. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 2002, 100:549-556.
16. Domingues M.J., Rambow F., Job B., Papon L., Liu W., Larue L., Bonaventure J. Beta-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res. 2014, 74:1983-1995.
17. Ragnarsson G., Eiriksdottir G., Johannsdottir J.T., Jonasson J.G., Egilsson V., Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer 1999, 79:1468-1474.
18. Bieche I., Khodja A., Lidereau R. Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Gene Chromosome Cancer 1999, 24:255-263.
19. Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N., Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R. MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in the cytoplasm. Int. J. Cancer 2015, 136:55-64.
20. Fukuyama R., Niculaita R., Ng K.P., Obusez E., Sanchez J., Kalady M., Aung P.P., Casey G., Sizemore N. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene 2008, 27:6044-6055.
21. Arnaud C., Sebbagh M., Nola S., Audebert S., Bidaut G., Hermant A., Gayet O., Dusetti N.J., Ollendorff V., Santoni M.J., Borg J.P., Lecine P. MCC, a new interacting protein for Scrib, is required for cell migration in epithelial cells. FEBS Lett. 2009, 583:2326-2332.
22. Medeiros A.C., Nagai M.A., Neto M.M., Brentani R.R. Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas. Cancer Epidemiol. Biomark. Prev. 1994, 3:331-333.
23. Thompson A.M., Morris R.G., Wallace M., Wyllie A.H., Steel C.M., Carter D.C. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br. J. Cancer 1993, 68:64-68.
24. Kohonen-Corish M.R., Sigglekow N.D., Susanto J., Chapuis P.H., Bokey E.L., Dent O.F., Chan C., Lin B.P., Seng T.J., Laird P.W., Young J., Leggett B.A., Jass J.R., Sutherland R.L. Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene 2007, 26:4435-4441.
25. Schlange T., Matsuda Y., Lienhard S., Huber A., Hynes N.E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007, 9:R63.
26. He Y., Liu Z., Qiao C., Xu M., Yu J., Li G. Expression and significance of Wnt signaling components and their target genes in breast carcinoma. Mol. Med. Rep. 2014, 9:137-143.
27. Schade B., Lesurf R., Sanguin-Gendreau V., Bui T., Deblois G., O'Toole S.A., Millar E.K., Zardawi S.J., Lopez-Knowles E., Sutherland R.L., Giguere V., Kahn M., Hallett M., Muller W.J. Beta-catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res. 2013, 73:4474-4487.
28. Valenta T., Hausmann G., Basler K. The many faces and functions of beta-catenin. EMBO J. 2012, 31:2714-2736.
29. van Veelen W., Le N.H., Helvensteijn W., Blonden L., Theeuwes M., Bakker E.R., Franken P.F., van Gurp L., Meijlink F., van der Valk M.A., Kuipers E.J., Fodde R., Smits R. Beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011, 60:1204-1212.
30. Dasgupta S., Mukherjee N., Roy S., Roy A., Sengupta A., Roychowdhury S., Panda C.K. Mapping of the candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of an Indian patient population. Oral Oncol. 2002, 38:6-15.
31. Loginov V.I., Maliukova A.V., Seregin Iu A., Khodyrev D.S., Kazubskaia T.P., Ermilova V.D., Gar'kavtseva R.F., Kiselev L.L., Zabarovskii E.R., Braga E.A. Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors. Mol. Biol. 2004, 38:654-667.
32. Costa-Guda J., Arnold A. Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 2007, 92:1564-1566.
33. Graham T.A., Clements W.K., Kimelman D., Xu W. The crystal structure of the beta-catenin/ICAT complex reveals the inhibitory mechanism of ICAT. Mol. Cell 2002, 10:563-571.
34. Chunder N., Mandal S., Basu D., Roy A., Roychoudhury S., Panda C.K. Deletion mapping of chromosome 1 in early onset and late onset breast tumors-a comparative study in eastern India. Pathol. Res. Pract. 2003, 199:313-321.
35. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408. (San Diego Calif.).
36. Sinha S., Singh R.K., Bhattacharya N., Mukherjee N., Ghosh S., Alam N., Roy A., Roychoudhury S., Panda C.K. Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications. Mol. Oncol. 2011, 5:454-464.
37. Perrone F., Suardi S., Pastore E., Casieri P., Orsenigo M., Caramuta S., Dagrada G., Losa M., Licitra L., Bossi P., Staurengo S., Oggionni M., Locati L., Cantu G., Squadrelli M., Carbone A., Pierotti M.A., Pilotti S. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2006, 12:6643-6651.
38. Borg A., Zhang Q.X., Olsson H., Wenngren E. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosom. Cancer 1992, 5:311-320.
39. Poursoltan P., Currey N., Pangon L., van Kralingen C., Selinger C.I., Mahar A., Cooper W.A., Kennedy C.W., McCaughan B.C., Trent R., Kohonen-Corish M.R. Loss of heterozygosity of the mutated in colorectal cancer gene is not associated with promoter methylation in non-small cell lung cancer. Lung Cancer 2012, 77:272-276. (Amsterdam, Netherlands).
40. Koyama T., Tago K., Nakamura T., Ohwada S., Morishita Y., Yokota J., Akiyama T. Mutation and expression of the beta-catenin-interacting protein ICAT in human colorectal tumors. Jpn. J. Clin. Oncol. 2002, 32:358-362.
41. Mukherjee N., Islam M.S., Roychowdhury A., Bhattacharya R., Chunder N., Bhattacharya N., Sinha S., Alam N., Roy A., Roychoudhury S., Panda C.K. The stem cell renewal and DNA damage response pathways are frequently altered in fibroepithelial tumors of breast in Indian patients. Pathol. Res. Pract. 2016, 212:196-203.
42. Sud R., Talbot I.C., Delhanty J.D. Infrequent alterations of the APC and MCC genes in gastric cancers from British patients. Br. J. Cancer 1996, 74:1104-1108.
43. Huang Y., Boynton R.F., Blount P.L., Silverstein R.J., Yin J., Tong Y., McDaniel T.K., Newkirk C., Resau J.H., Sridhara R., Reid B.J., Meltzer S.J. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res. 1992, 52:6525-6530.
44. Shukla R., Upton K.R., Munoz-Lopez M., Gerhardt D.J., Fisher M.E., Nguyen T., Brennan P.M., Baillie J.K., Collino A., Ghisletti S., Sinha S., Iannelli F., Radaelli E., Dos Santos A., Rapoud D., Guettier C., Samuel D., Natoli G., Carninci P., Ciccarelli F.D., Garcia-Perez J.L., Faivre J., Faulkner G.J. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell 2013, 153:101-111.
45. Lim L., Balakrishnan A., Huskey N., Jones K.D., Jodari M., Ng R., Song G., Riordan J., Anderton B., Cheung S.T., Willenbring H., Dupuy A., Chen X., Brown D., Chang A.N., Goga A. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2013, 59:202-215. (Baltimore, MD).
46. Edwards S.K., Baron J., Moore C.R., Liu Y., Perlman D.H., Hart R.P., Xie P. Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes. J. Hematol. Oncol. 2014, 7:56.
47. Incassati A., Chandramouli A., Eelkema R., Cowin P. Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res. 2010, 12:213.
48. Sanz-Ortega J., Bryant B., Sanz-Esponera J., Asenjo J.A., Saez M.C., Torres A., Balibrea J.L., Sobel M.E., Merino M.J. LOH at the APC/MCC gene (5Q21) is frequent in early stages of non-small cell lung cancer. Pathol. Res. Pract. 1999, 195:677-680.
49. Sanz-Ortega J., Sanz-Esponera J., Caldes T., Gomez de la Concha E., Sobel M.E., Merino M.J. LOH at the APC/MCC gene (5Q21) in gastric cancer and preneoplastic lesions: prognostic implications. Pathol. Res. Pract. 1996, 192:1206-1210.
50. Wu Y., Ginther C., Kim J., Mosher N., Chung S., Slamon D., Vadgama J.V. Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res. 2012, 10:1597-1606.
51. Prasad C.P., Gupta S.D., Rath G., Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology 2007, 73:112-117.
52. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., Pestell R.G., Hung M.C. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4262-4266.
53. Kappler C.S., Guest S.T., Irish J.C., Garrett-Mayer E., Kratche Z., Wilson R.C., Ethier S.P. Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer. Mol. Oncol. 2015, 9:527-543.
54. Xi Y., Wei Y., Sennino B., Ulsamer A., Kwan I., Brumwell A.N., Tan K., Aghi M.K., McDonald D.M., Jablons D.M., Chapman H.A. Identification of pY654-beta-catenin as a critical co-factor in hypoxia-inducible factor-1alpha signaling and tumor responses to hypoxia. Oncogene 2013, 32:5048-5057.